PriceTargets.com logo

uniQure - QURE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $19.50
  • Forecasted Upside: 209.52%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.30 As of 10/30/2024 03:53 PM ET
▼ -0.12 (-1.87%)

This chart shows the closing price for QURE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New uniQure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QURE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QURE

Analyst Price Target is $19.50
▲ +209.52% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for uniQure in the last 3 months. The average price target is $19.50, with a high forecast of $28.00 and a low forecast of $6.00. The average price target represents a 209.52% upside from the last price of $6.30.

This chart shows the closing price for QURE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in uniQure. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/10/2024Raymond JamesReiterated RatingOutperform$20.00
9/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$28.00 ➝ $28.00
8/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
8/2/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$6.00 ➝ $10.00
7/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$24.00 ➝ $24.00
7/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00
5/8/2024MizuhoLower TargetNeutral ➝ Neutral$7.00 ➝ $6.00
3/4/2024MizuhoLower TargetNeutral ➝ Neutral$10.00 ➝ $7.00
3/1/2024HC WainwrightLower TargetBuy ➝ Buy$30.00 ➝ $25.00
2/29/2024The Goldman Sachs GroupDowngradeBuy ➝ Neutral$63.00 ➝ $8.00
1/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
1/16/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$28.00
12/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$21.00
12/19/2023MizuhoDowngradeBuy ➝ Neutral$52.00 ➝ $10.00
11/7/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$56.00 ➝ $63.00
8/17/2023Chardan CapitalReiterated RatingBuy
8/2/2023Raymond JamesLower TargetOutperform ➝ Outperform$56.00 ➝ $50.00
8/2/2023HC WainwrightLower TargetBuy ➝ Buy$90.00 ➝ $30.00
8/2/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$47.00 ➝ $42.00
7/10/2023Chardan CapitalReiterated RatingBuy
6/23/2023GuggenheimLower Target$53.00 ➝ $46.00
6/22/2023Wells Fargo & CompanyLower Target$24.00 ➝ $14.00
5/19/2023UBS GroupLower Target$45.00 ➝ $42.00
5/11/2023Truist FinancialLower Target$65.00 ➝ $55.00
5/10/2023Chardan CapitalLower Target$60.00 ➝ $56.00
3/7/2023HC WainwrightReiterated RatingBuy$90.00
2/28/2023GuggenheimReiterated RatingBuy$53.00
2/28/2023Credit Suisse GroupBoost TargetOutperform$51.00 ➝ $55.00
2/28/2023Chardan CapitalReiterated RatingBuy$60.00
11/23/2022The Goldman Sachs GroupBoost TargetBuy$47.00 ➝ $57.00
11/23/2022Truist FinancialBoost Target$51.00 ➝ $65.00
11/3/2022Cantor FitzgeraldReiterated RatingOverweight
11/3/2022The Goldman Sachs GroupLower TargetBuy$54.00 ➝ $48.00
11/2/2022William BlairReiterated RatingOutperform
8/9/2022Chardan CapitalLower TargetBuy$65.00 ➝ $60.00
8/9/2022Wells Fargo & CompanyLower TargetEqual Weight$34.00 ➝ $24.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$59.00 ➝ $51.00
5/5/2022Stifel NicolausLower Target$66.00 ➝ $37.00
4/13/2022Truist FinancialLower Target$90.00 ➝ $51.00
3/30/2022Chardan CapitalLower Target$95.00 ➝ $65.00
3/22/2022Chardan CapitalReiterated RatingBuy
3/17/2022UBS GroupUpgradeNeutral ➝ Buy$40.00
12/16/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$75.00 ➝ $58.00
10/27/2021William BlairInitiated CoverageOutperform$66.00
10/26/2021Cantor FitzgeraldReiterated RatingOverweight
9/14/2021Leerink PartnersReiterated RatingBuy
7/27/2021Credit Suisse GroupReiterated RatingOutperform$78.00 ➝ $27.46
7/27/2021Chardan CapitalReiterated RatingBuy$100.00 ➝ $95.00
7/1/2021Chardan CapitalReiterated RatingBuy
6/14/2021BTIG ResearchInitiated CoverageBuy$46.00
5/31/2021Leerink PartnersReiterated RatingBuy
5/20/2021UBS GroupInitiated CoverageNeutral$40.00
5/19/2021HC WainwrightBoost TargetBuy$80.00 ➝ $90.00
4/1/2021MizuhoUpgradeNeutral ➝ Buy$52.00
3/2/2021Chardan CapitalBoost TargetBuy$85.00 ➝ $100.00
1/7/2021GuggenheimUpgradeNeutral ➝ Buy$62.00
12/22/2020Royal Bank of CanadaBoost TargetHold ➝ Outperform$53.00 ➝ $61.00
12/21/2020HC WainwrightBoost TargetHold ➝ Buy$80.00 ➝ $85.00
12/9/2020Jefferies Financial GroupBoost TargetPositive ➝ Buy$55.00 ➝ $62.00
12/9/2020MizuhoBoost TargetNeutral$46.00 ➝ $52.00
11/24/2020HC WainwrightInitiated CoverageBuy$80.00
11/20/2020Credit Suisse GroupBoost TargetOutperform$76.00 ➝ $78.00
11/11/2020Berenberg BankInitiated CoverageBuy$59.00
11/9/2020Jefferies Financial GroupInitiated CoverageBuy$55.00
11/4/2020Cantor FitzgeraldInitiated CoverageOverweight$65.00
10/28/2020MizuhoLower TargetNeutral$61.00 ➝ $46.00
10/22/2020Royal Bank of CanadaInitiated CoverageOutperform$61.00
10/9/2020Cantor FitzgeraldReiterated RatingOverweight
8/24/2020Raymond JamesInitiated CoverageStrong-Buy$75.00
8/11/2020Chardan CapitalReiterated RatingBuy$80.00
7/31/2020Credit Suisse GroupReiterated RatingBuy$76.00
7/31/2020Robert W. BairdUpgradeNeutral ➝ Outperform$58.00 ➝ $57.00
7/14/2020MizuhoReiterated RatingHold$61.00
6/25/2020Chardan CapitalLower TargetBuy$105.00 ➝ $80.00
6/25/2020HC WainwrightLower TargetBuy$73.00 ➝ $64.00
6/25/2020Stifel NicolausLower TargetBuy$86.00 ➝ $78.00
6/25/2020MizuhoReiterated RatingBuy ➝ Neutral$90.00 ➝ $61.00
6/25/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$90.00 ➝ $56.00
6/25/2020Robert W. BairdDowngradeOutperform ➝ Neutral$58.00
6/19/2020HC WainwrightReiterated RatingBuy$73.00
5/29/2020Chardan CapitalReiterated RatingBuy$105.00
5/8/2020Chardan CapitalReiterated RatingBuy$105.00
4/30/2020MizuhoReiterated RatingBuy$90.00
3/3/2020HC WainwrightReiterated RatingBuy$73.00
3/3/2020Chardan CapitalLower TargetBuy$125.00 ➝ $105.00
2/10/2020HC WainwrightReiterated RatingBuy$73.00
1/29/2020Chardan CapitalReiterated RatingBuy$125.00
1/23/2020Cantor FitzgeraldBoost TargetOverweight$94.00 ➝ $96.00
12/23/2019HC WainwrightReiterated RatingBuy$73.00
12/20/2019SunTrust BanksInitiated CoverageBuy$90.00
12/10/2019MizuhoReiterated RatingBuy$67.00 ➝ $90.00
12/9/2019HC WainwrightReiterated RatingBuy$73.00
12/9/2019Chardan CapitalReiterated RatingBuy$125.00
12/3/2019Piper Sandler CompaniesReiterated RatingBuy$80.00
12/3/2019CowenInitiated CoverageOutperform
12/3/2019The Goldman Sachs GroupInitiated CoverageBuy$98.00
11/5/2019Credit Suisse GroupInitiated CoverageOutperform$76.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
uniQure logo
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $6.30
Low: $6.25
High: $6.48

50 Day Range

MA: $5.73
Low: $4.54
High: $7.03

52 Week Range

Now: $6.30
Low: $3.73
High: $11.35

Volume

443,650 shs

Average Volume

1,428,129 shs

Market Capitalization

$306.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of uniQure?

The following equities research analysts have issued research reports on uniQure in the last twelve months: Cantor Fitzgerald, HC Wainwright, Mizuho, Raymond James, Royal Bank of Canada, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for QURE.

What is the current price target for uniQure?

6 Wall Street analysts have set twelve-month price targets for uniQure in the last year. Their average twelve-month price target is $19.50, suggesting a possible upside of 203.7%. Royal Bank of Canada has the highest price target set, predicting QURE will reach $28.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $6.00 for uniQure in the next year.
View the latest price targets for QURE.

What is the current consensus analyst rating for uniQure?

uniQure currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for QURE.

What other companies compete with uniQure?

Other companies that are similar to uniQure include Evotec, Avadel Pharmaceuticals, ANI Pharmaceuticals, Gyre Therapeutics and Praxis Precision Medicines. Learn More about companies similar to uniQure.

How do I contact uniQure's investor relations team?

uniQure's physical mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company's listed phone number is (120) 240-6000 and its investor relations email address is investors@uniqure. The official website for uniQure is www.uniqure.com. Learn More about contacing uniQure investor relations.